These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. The rationale of combination antifungal therapy in severely immunocompromised patients: empiricism versus evidence-based medicine. Chamilos G; Kontoyiannis DP Curr Opin Infect Dis; 2006 Aug; 19(4):380-5. PubMed ID: 16804387 [TBL] [Abstract][Full Text] [Related]
24. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. Metcalf SC; Dockrell DH J Infect; 2007 Oct; 55(4):287-99. PubMed ID: 17697716 [TBL] [Abstract][Full Text] [Related]
25. Changing epidemiology of systemic fungal infections. Richardson M; Lass-Flörl C Clin Microbiol Infect; 2008 May; 14 Suppl 4():5-24. PubMed ID: 18430126 [TBL] [Abstract][Full Text] [Related]
26. Role of complement in innate immunity and host defense. Trouw LA; Daha MR Immunol Lett; 2011 Jul; 138(1):35-7. PubMed ID: 21333684 [TBL] [Abstract][Full Text] [Related]
27. Controlling pathogenic inflammation to fungi. Romani L; Puccetti P Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1007-17. PubMed ID: 18039084 [TBL] [Abstract][Full Text] [Related]
28. Role of the dual interaction of fungal pathogens with pattern recognition receptors in the activation and modulation of host defence. Netea MG; Van der Meer JW; Kullberg BJ Clin Microbiol Infect; 2006 May; 12(5):404-9. PubMed ID: 16643515 [TBL] [Abstract][Full Text] [Related]
29. Role of Toll-like receptors in lung innate defense against invasive aspergillosis. Distinct impact in immunocompetent and immunocompromized hosts. Chignard M; Balloy V; Sallenave JM; Si-Tahar M Clin Immunol; 2007 Sep; 124(3):238-43. PubMed ID: 17604224 [TBL] [Abstract][Full Text] [Related]
30. [Frontier of mycobacterium research--host vs. mycobacterium]. Okada M; Shirakawa T Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793 [TBL] [Abstract][Full Text] [Related]
31. Innate immunity against moulds: lessons learned from invertebrate models. Ben-Ami R Immunol Invest; 2011; 40(7-8):676-91. PubMed ID: 21985301 [TBL] [Abstract][Full Text] [Related]
32. Immunomodulatory therapy in yeast infections. Garbino J; Katragkou A; Roilides E Expert Rev Anti Infect Ther; 2007 Feb; 5(1):129-40. PubMed ID: 17266460 [TBL] [Abstract][Full Text] [Related]
34. Dendritic cells and complement: at the cross road of innate and adaptive immunity. Castellano G; Woltman AM; Schena FP; Roos A; Daha MR; van Kooten C Mol Immunol; 2004 Jun; 41(2-3):133-40. PubMed ID: 15159058 [TBL] [Abstract][Full Text] [Related]
35. [Current role of deep mycoses in infectious pathology]. Drouhet E Rev Prat; 1989 Sep; 39(19):1651-6. PubMed ID: 2814246 [TBL] [Abstract][Full Text] [Related]
36. Evaluation and management of fungal infections in immunocompromised patients. Venkatesan P; Perfect JR; Myers SA Dermatol Ther; 2005; 18(1):44-57. PubMed ID: 15842612 [TBL] [Abstract][Full Text] [Related]
37. Recent advances on the complement system of teleost fish. Boshra H; Li J; Sunyer JO Fish Shellfish Immunol; 2006 Feb; 20(2):239-62. PubMed ID: 15950490 [TBL] [Abstract][Full Text] [Related]
40. Trends in the postmortem diagnosis of opportunistic invasive fungal infections in patients with AIDS: a retrospective study of 1,630 autopsies performed between 1984 and 2002. Antinori S; Nebuloni M; Magni C; Fasan M; Adorni F; Viola A; Corbellino M; Galli M; Vago G; Parravicini C; Ridolfo AL Am J Clin Pathol; 2009 Aug; 132(2):221-7. PubMed ID: 19605816 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]